University of Michigan School of Social Work

The MolinaCares Accord Donates $100,000 to University of Michigan for Health Equity Challenge

Retrieved on: 
Wednesday, November 8, 2023

The MolinaCares Accord (“MolinaCares”), in collaboration with Molina Healthcare of Michigan (“Molina”), announced a $100,000 grant to the University of Michigan School of Public Health (“U-M”) that will fund the Michigan Health Equity Challenge, an effort inspiring students to develop innovative solutions to Michigan’s most pressing health equity concerns.

Key Points: 
  • The MolinaCares Accord (“MolinaCares”), in collaboration with Molina Healthcare of Michigan (“Molina”), announced a $100,000 grant to the University of Michigan School of Public Health (“U-M”) that will fund the Michigan Health Equity Challenge, an effort inspiring students to develop innovative solutions to Michigan’s most pressing health equity concerns.
  • Through the Michigan Health Equity Challenge, U-M graduate students are invited to create practical, innovative community-based solutions to address health disparities that persist in Michigan.
  • “Eliminating systemic barriers to healthy outcomes takes imagination, collaboration, and passion; the MolinaCares Michigan Health Equity Challenge will help provide the resources to foster needed solutions,” said Terrisca Des Jardins, plan president for Molina Healthcare of Michigan.
  • Thanks to MolinaCares, students who win the Health Equity Challenge will be able to transform their proposals into actionable initiatives, address historical inequities in health care, and change lives.”
    For details about the Michigan Health Equity Challenge, in partnership with The MolinaCares Accord, please visit mihealthequitychallenge.org .

Molina Healthcare of Michigan and The MolinaCares Accord Invest $4.5 Million to Improve Health Equity for Underserved Michiganders

Retrieved on: 
Friday, October 20, 2023

Molina Healthcare of Michigan (“Molina”), in collaboration with The MolinaCares Accord (“MolinaCares”), is launching the MolinaCares Michigan Health Equity Initiative, investing an initial $4.5 million in a multi-faceted, community-focused strategy to improve equity and health outcomes for underserved populations.

Key Points: 
  • Molina Healthcare of Michigan (“Molina”), in collaboration with The MolinaCares Accord (“MolinaCares”), is launching the MolinaCares Michigan Health Equity Initiative, investing an initial $4.5 million in a multi-faceted, community-focused strategy to improve equity and health outcomes for underserved populations.
  • Molina has launched multiple mobile medical unit partnerships in communities where medical visits are low and health needs are high.
  • In partnership with Wayne State University Wayne Health Mobile Unit, Molina is providing Detroit area members with comprehensive services needed to improve health outcomes.
  • MolinaCares is collaborating with Michigan State University Institute for Health Policy and the University of Michigan School of Public Health to inform and build novel solutions to address factors that contribute to recurring local health disparities to advance health equity through a member advisory group and student health equity challenge, respectively.

RELYVRIO® and AMX0114 Data to be Presented at 22nd Annual Northeast ALS Consortium (NEALS) Meeting

Retrieved on: 
Monday, October 2, 2023

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced the acceptance of several abstracts for presentation at the hybrid 2023 Northeast ALS Consortium (NEALS) Annual Meeting.

Key Points: 
  • Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced the acceptance of several abstracts for presentation at the hybrid 2023 Northeast ALS Consortium (NEALS) Annual Meeting.
  • The data being shared are related to AMX0035 (sodium phenylbutyrate and taurursodiol [PB&TURSO]) and the Company’s investigational antisense oligonucleotide, AMX0114, for the potential treatment of amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.
  • AMX0035 is marketed by Amylyx as RELYVRIO® and is approved to treat ALS in adults in the U.S. and approved with conditions as ALBRIOZA™ for the treatment of ALS in Canada.
  • The in-person component of the NEALS Annual Meeting will take place in Clearwater, Florida October 4-6, 2023.

WANDA joins the Collaboration on Equitable Health and receives funding to improve health outcomes in communities of color

Retrieved on: 
Friday, September 15, 2023

The Collaboration for Equitable Health, backed by a substantial $25 million investment over four years, has a clear mission: to enhance health outcomes within marginalized communities, including Black, Hispanic/Latino, Asian American, and Native American populations.

Key Points: 
  • The Collaboration for Equitable Health, backed by a substantial $25 million investment over four years, has a clear mission: to enhance health outcomes within marginalized communities, including Black, Hispanic/Latino, Asian American, and Native American populations.
  • This initiative addresses leading causes of mortality in these communities, which include heart disease, cancer, stroke, and diabetes.
  • The first step to improve health outcomes is to provide community resources and ensure that members of these communities have adequate access to these resources and care."
  • Furthermore, they will be part of a collective effort advocating for change to achieve health equity for all.

Teva to Present Data Demonstrating UZEDY™ (risperidone) Extended-Release Injectable Suspension Significantly Prolonged Time to Impending Relapse for Adults with Schizophrenia at the American Psychiatric Association’s 2023 Annual Meeting

Retrieved on: 
Saturday, May 20, 2023

Abstracts include data for UZEDY (risperidone) extended-release injectable suspension for subcutaneous use, which was recently approved by the FDA for the treatment of schizophrenia in adults.

Key Points: 
  • Abstracts include data for UZEDY (risperidone) extended-release injectable suspension for subcutaneous use, which was recently approved by the FDA for the treatment of schizophrenia in adults.
  • Additional abstracts being presented include data on characteristics that impact TD diagnosis and machine-learning to identify unique patient segments for TD.
  • UZEDY utilizes SteadyTeq™, a copolymer technology proprietary to MedinCell, that controls the rate and duration of risperidone release.
  • This year’s annual APA meeting is being offered both in person and virtually.

King’s University College social work students able to help more families as TD Bank Group makes three-year commitment to support and expand SAFE program

Retrieved on: 
Tuesday, March 14, 2023

TD’s donation supports the growth of the SAFE program, which is operated by students enrolled in the Master of Social Work and Bachelor of Social Work programs at King’s University College.

Key Points: 
  • TD’s donation supports the growth of the SAFE program, which is operated by students enrolled in the Master of Social Work and Bachelor of Social Work programs at King’s University College.
  • Launched in 2021 as a pilot program to assist families within the Thames Valley District School Board (TVDSB), SAFE provides immediate intake and counselling to families who are struggling.
  • It offers valuable mental health services at no cost, with no wait times, no cap on sessions, and with the convenience of virtual delivery.
  • “Families appreciated having quick access to an effective source of emotional support, helpful strategies, and a non-judgemental person to lean on,” she says.

Teva Announces Publication of New Clinician Scale in Journal of Clinical Psychiatry to Assess the Impact of Tardive Dyskinesia on Patients’ Lives

Retrieved on: 
Thursday, February 23, 2023

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the print publication of the IMPACT-TD Scale, an easy-to-use, standardized and clinician-rated assessment.

Key Points: 
  • Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the print publication of the IMPACT-TD Scale, an easy-to-use, standardized and clinician-rated assessment.
  • The scale, developed by a consensus panel, will assist healthcare providers in determining the impact of tardive dyskinesia (TD) on different aspects of a patient’s daily functioning.
  • IMPACT-TD categorizes the consequences of TD symptoms into multiple functional domains: social, psychological/psychiatric, physical and vocational/educational/recreational.
  • The consensus panel and published statement were sponsored by an independent medical grant from Teva.

Assessing how much inpatient care information patients retain after hospital discharge

Retrieved on: 
Tuesday, January 31, 2023

OAKBROOK TERRACE, Illinois, Jan. 31, 2023 (GLOBE NEWSWIRE) -- (OAKBROOK TERRACE, Illinois, January 31, 2023) – Hospitalized patients receive a large amount of medical information from their healthcare team.

Key Points: 
  • OAKBROOK TERRACE, Illinois, Jan. 31, 2023 (GLOBE NEWSWIRE) -- (OAKBROOK TERRACE, Illinois, January 31, 2023) – Hospitalized patients receive a large amount of medical information from their healthcare team.
  • Patient understanding of medical care reduces readmission rates and improves patient satisfaction, yet the literature suggests that patients often have poor retention of the large amount of care information they received despite numerous interventions.
  • A new study in the February 2023 issue of The Joint Commission Journal on Quality and Patient Safety (JQPS) evaluated how well patients retain care information after hospital discharge and assessed patient perspectives on facilitators of this process, such as whiteboards, discussions with providers, discharge paperwork and patient portal.
  • Patients suggested several areas for improvement, including prioritizing bedside pen and paper along with updating whiteboards with diagnostic and therapeutic information.

Michigan Students Plan School Choice Celebration at State Capitol for January 26

Retrieved on: 
Thursday, January 19, 2023

Next week, students who benefited from the state's growing school choice options are sharing their inspirational stories at a high-energy rally at the State Capitol in Lansing.

Key Points: 
  • Next week, students who benefited from the state's growing school choice options are sharing their inspirational stories at a high-energy rally at the State Capitol in Lansing.
  • The event will be held on Thursday, January 26, 2023, from 10:00 AM to 1:00 PM in Heritage Hall of the Michigan Capitol (100 North Capitol Avenue in Lansing).
  • "This event will educate even more parents about our state's school choice offerings, while celebrating the transformational benefits of K–12 school choice."
  • National School Choice Week (NSCW) informs, inspires, and empowers parents to discover the K-12 education options available for their children.

Oak Street Health Launches Nurse Practitioner Fellowship in Adult Primary Care

Retrieved on: 
Tuesday, September 20, 2022

Oak Street Health is committed to providing high-quality primary care and an unmatched patient experience, and that begins with our exceptional team of providers, said Dr. Julie Silverstein, Chief Medical Officer, Care Delivery of Oak Street Health.

Key Points: 
  • Oak Street Health is committed to providing high-quality primary care and an unmatched patient experience, and that begins with our exceptional team of providers, said Dr. Julie Silverstein, Chief Medical Officer, Care Delivery of Oak Street Health.
  • Oak Street Health delivers personalized, preventive primary care through a model that was created to meet the unique needs of older adults.
  • Founded in 2012, Oak Street Health is a network of value-based primary care centers for adults on Medicare.
  • Oak Street Health currently operates more than 150 centers across 20 states and is the only primary care provider to carry the AARP name.